Pharma BD Deal Intelligence
A $1.0B GSK acquisition of Aiolos Bio to grab AIO-001, a long-acting anti-TSLP antibody dosed as infrequently as twice yearly, aimed squarely at Amgen/AstraZeneca's Tezspire in asthma. The bet remains unproven though—AIO-001 only entered Phase 2 dosing trials in February 2025, over a year post-close.
GSK puts $1.4B on the line in Aiolos acquisition to boost asthma pipeline with Phase II-ready anti-TSLP monoclonal antibody AIO-001
ClinicalTrials.gov NCT06748053 (Tier 4 primary registry record): Phase 2, multicentre, randomized, double-blind, placebo-controlled, dose-finding study of…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
GSK acquired Aiolos Bio for $1.0B upfront plus up to $400M in success-based regulatory milestones (announced 2024-01-09, completed 2024-02-15) to add a Phase 2-ready, long-acting anti-TSLP monoclonal antibody, AIO-001 (now GSK5784283; also SHR-1905), to its respiratory franchise. AIO-001's potency and half-life extension support potential dosing as infrequently as every six months for adult asthma, positioning GSK against Amgen/AstraZeneca's Tezspire. The asset entered a Phase 2 dose-finding asthma study (NCT06748053) in February 2025.
250K US cases/yr · $8.5B Global Severe Asthma Biologics (2025E)
Severe asthma is chronic airway inflammation that remains uncontrolled despite high-dose inhaled corticosteroids plus a second controller, or requires such therapy to prevent loss of control. It affects roughly 5-10% of the ~25 million US asthma patients and is characterized by recurrent exacerbations, frequent OCS exposure, and lung function decline. Phenotypes include T2-high (eosinophilic/allergic) and T2-low disease. Biologics now target IgE (omalizumab), IL-5/IL-5R (mepolizumab, reslizumab, benralizumab), IL-4Rα (dupilumab), and TSLP (tezepelumab).
AZ Tezspire (~$1.5B 2024) validated TSLP target. AIO-001 differentiates on dosing interval (q6m vs Tezspire q4w). Competes with anti-IL5, anti-IgE biologics.
The CRSwNP biologics market is a Type 2 inflammation battleground anchored by four approved mAbs across four distinct MOAs. Anti-IL-4Ra: Dupixent (dupilumab, Sanofi/Regeneron) is the clear category leader, approved in 2019 and generating >$14B in 2024 worldwide net sales across all indications, with CRSwNP a key growth driver. Anti-IL-5/5R: Nucala (mepolizumab, GSK) received FDA approval for CRSwNP in 2021 (Q4W subcutaneous), while Fasenra (benralizumab, AstraZeneca) failed its pivotal OSTRO trial and is not CRSwNP-approved. Anti-IgE: Xolair (omalizumab, Genentech/Novartis) was approved for CRSwNP in 2020 but has modest uptake versus dupilumab given inferior polyp-score reductions. Anti-TSLP: Tezspire (tezepelumab, Amgen/AstraZeneca) reported positive Phase 3 WAYPOINT data in CRSwNP in 2024 and filed sBLA, positioning as the upstream-alarmin alternative covering non-Type-2-high patients. Aiolos's AIO-001, a long-acting anti-TSLP mAb engineered for Q6M dosing, competes most directly with tezepelumab (Q4W) on dosing convenience and with dupilumab on breadth. Commercial threat assessment: dupilumab's biologic-experienced physician loyalty and broad atopic halo remain the dominant share anchor; AIO-001's differentiated dose interval is the only credible wedge, contingent on non-inferior SNOT-22 and NPS outcomes versus tezepelumab.
GSK completed $1B+ acquisition of Aiolos Bio, gaining AIO-001, long-acting anti-TSLP antibody for asthma with less frequent dosing potential.
GSK advanced AIO-001 as potential long-acting competitor to AstraZeneca's Tezspire in anti-TSLP asthma market.
AIO-001 (GSK5784283) began a Phase 2 dose-finding study in uncontrolled asthma (NCT06748053), confirming on-schedule advancement of the asset GSK acquired with Aiolos. Active, not recruiting; primary completion est. mid-2026.
AIO-001 fits GSK respiratory franchise with potentially best-in-class dosing. Early clinical. $1B targets growing biologics-for-asthma market.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GSK plc / Aiolos Bio (this deal) | 2024 | $1.0B | 60 |
| GSK plc / SmithKline Beecham | 2000 | $12.0B | 79 |
| GSK plc / Pfizer Inc. | 2018 | $0.0M | 77 |
| GSK plc / Novartis AG | 2014 | $16.0B | 76 |
| GSK plc / Hansoh Pharmaceutical Group Co. Ltd. | 2023 | $1.7B | 74 |
| GSK plc / Nuvalent, Inc. | 2026 | $10.6B | 70 |
| GSK plc / Sierra Oncology Inc. | 2022 | $1.9B | 70 |
← Browse all deals · How we score deals
More: 2024 deals · GSK plc deals · Respiratory deals